2-(氯甲基)-5-甲基噻吩[2,3-D]嘧啶-4(3H)-酮 | 568577-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 2-(氯甲基)-5-甲基噻吩[2,3-D]嘧啶-4(3H)-酮
• 中文别名: 2-(氯甲基)-5-甲基噻吩并[2,3-d]嘧啶-4(3H)-酮；2-氯甲基-5-甲基噻吩并[2,3-d]嘧啶-4(3h-)-酮
• 英文名称: 2-(chloromethyl)-5-methyl-3H-thieno[2,3-d]pyrimidin-4-one
• CAS: 568577-81-1
• 化学式: C₈H₇ClN₂OS
• 分子量: 214.675
• InChiKey: NPCDJJHBOSYDKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  2-(氯甲基)-5-甲基噻吩[2,3-D]嘧啶-4(3H)-酮 在 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.25h， 生成 methyl 2-(5-methyl-4-oxo-2-((pyrrolidin-1-yl)methyl)thieno[2,3-d]pyrimidin-3(4H)-yl)acetate
  参考文献：
  名称：

  Allosteric Inhibition of a Mammalian Lectin

  摘要：

  Glycan-binding proteins are key components of central physiological and cellular processes such as self-/non-self-recognition, cellular tissue homing, and protein homeostasis. Herein, C-type lectins are a diverse protein family that play important roles in the immune system, rendering them attractive drug targets. To evaluate C-type lectin receptors as target proteins for small-molecule effectors, chemical probes are required, which are, however, still lacking. To overcome the supposedly poor druggability of C-type lectin receptors and to identify starting points for chemical probe development, we screened murine langerin using H-1 and F-19 NMR against a library of 871 drug-like fragments. Subsequently, hits were validated by surface plasmon resonance and enzyme-linked lectin assay. Using structure activity relationship studies and chemical synthesis, we identified thiazolopyrimidine derivatives with double-digit micromolar activity that displayed langerin selectivity. Based on H-10-N-15 HSQC NMR and competitive binding and inhibition experiments, we demonstrate that thiazolopyrimidines allosterically inhibit langerin. To the best of our knowledge, this is the first report of drug-like allosteric inhibitors of a mammalian lectin.

  DOI：

  10.1021/jacs.8b08644

文献信息

• [EN] SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS PYRAZOLE SUBSTITUÉS ET LEUR UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009119880A1

  公开（公告）日：2009-10-01

  The present invention aims to provide a pyrazole derivative represented by the formula (I') or a salt thereof.

  本发明旨在提供由式(I')表示的吡唑衍生物或其盐。
• Substituted pyrazole derivatives and use thereof
  申请人：Ito Mitsuhiro

  公开号：US20090270361A1

  公开（公告）日：2009-10-29

  The present invention aims to provide a novel pyrazole derivative and a pharmaceutical agent containing the same. The present invention provides a compound represented by the formula (I′) wherein R 1 ′ is (1) a hydrogen atom, (2) a group via a carbon atom, (3) a group via a nitrogen atom, (4) a group via an oxygen atom or (5) a group via a sulfur atom; R 2 ′ is an aromatic ring group optionally having substituent(s); R 3 ′ is (1) a hydrogen atom, (2) a group via a carbon atom, (3) a group via a nitrogen atom, (4) a group via an oxygen atom or (5) a group via a sulfur atom; R 4 ′ is a cyanophenyl group optionally having substituent(s); X′ is (1) —Y′—CR 5 ′R 6 ′-Z′- wherein R 5 ′ and R 6 ′ are the same or different and each is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom, or —CR 5 ′R 6 ′— is —C(alkylidene)-; Y′ is a bond, —COCO—, —CONH—, —COCONH— or —O—; and Z′ is a bond, —CH 2 —, —CONH—, —O—, —OCH 2 —, —S—, —SO—, —SO 2 —, —CON(C 6 H 5 )— or (2) —CO(CONH) n — wherein n is 0 or 1, (3) —NHCO—, (4) —CONH—, (5) —O—, (6) —CH═CH— or (7) —O(C 1-3 alkylene)O—; (excluding the compounds indicated to be excluded from the specification), or a salt thereof.

  本发明旨在提供一种新型吡唑衍生物及其制备的药物。本发明提供一种化合物，其表示为公式（I'）： 其中，R1'是（1）氢原子，（2）通过碳原子的基团，（3）通过氮原子的基团，（4）通过氧原子的基团或（5）通过硫原子的基团；R2'是芳香环基团，可选地具有取代基；R3'是（1）氢原子，（2）通过碳原子的基团，（3）通过氮原子的基团，（4）通过氧原子的基团或（5）通过硫原子的基团；R4'是氰基苯基团，可选地具有取代基；X'是（1）-Y'-CR5'R6'-Z'-，其中R5'和R6'相同或不同，每个都是氢原子，通过碳原子的基团，通过氮原子的基团，通过氧原子的基团或通过硫原子的基团，或者-CR5'R6'-是-C（烷基亚基）-；Y'是键，-COCO-，-CONH-，-COCONH-或-O-；Z'是键，-CH2-，-CONH-，-O-，-O -，-S-，-SO-，-SO2-，-CON（C6H5）-或（2）-CO（CONH）n-，其中n为0或1，（3）-NHCO-，（4）-CONH-，（5）-O-，（6）-CH═CH-或（7）-O（C1-3烷基亚基）O-；（不包括规范中指定要排除的化合物）或其盐。
• [EN] ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES<br/>[FR] AMINES ACYCLIQUES INHIBITEURS DES PHOSPHORYLASES ET HYDROLASES DE NUCLÉOSIDES
  申请人：IND RES LTD

  公开号：WO2008030119A9

  公开（公告）日：2009-09-24

  [EN] The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
  [FR] La présente invention concerne des composes représentés par la formule générale (I), et des compositions pharmaceutiques contenant ces composés, lesquels composés sont des inhibiteurs des phosphorylases de nucléosides de purine (PNP) et/ou d'hydrolases de nucléosides (NH). L'invention concerne également l'utilisation de ces composés pour le traitement de maladies et d'infections dont le cancer, les infections bactériennes, les infections par protozoaires, et les maladies médiées par les lymphocytes T.